DOCSLIB.ORG

Biological Methylation: Fundamental Mechanisms in Human Health and Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biological Methylation: Fundamental Mechanisms in Human Health and Disease Biological Methylation: Fundamental Mechanisms in Human Health and Disease Hilton Florence Metropole Florence, Italy June 17 – 22, 2018 Co-organizers: Maria Elena Torres-Padilla, Ph.D. Associate Professor, Institute of Epigenetics and Stem Cells Helmholtz Zentrum München Xiaobing Shi, Ph.D. Professor, Center for Epigenetics Van Andel Research Institute Sunday, June 17 4:00-9:00pm Conference Registration 4:45-5:00pm Welcome from FASEB and the organizers Keynote address 5:00-6:00pm Kristian Helin, University of Copenhagen Histone methylation and human cancer 6:00-7:00pm Welcome reception 7:00-8:00pm DINNER Monday, June 18 7:30-9:00am BREAKFAST 7:30-12:00pm Conference Registration Session 1: Methylation and chromatin regulation 9:00-12:00pm Chair: Scott Rothbart, Van Andel Research Institute 9:00-9:30am Thomas Jenuwein, Max Planck Institute of Immunology and Epigenetics 9:30-10:00am Robert Schneider, Institute of Functional Epigenetics, Munich 10:00-10:30am Brian Strahl, University of North Carolina at Chapel Hill 10:30-11:00am Coffee break and GROUP PHOTO 11:00-11:30am Jerry Workman, Stowers Institute 11:30-11:45am Eric Selker, University of Pennsylvania 11:45-12:00pm Rochelle Tiedemann, Van Andel Research Institute 12:00-1:00pm LUNCH and Meet the Experts 1:00-2:00pm Career Development Workshops 2:00-4:00pm FREE AFTERNOON Keynote address 4:00-5:00pm Tom Muir, Princeton University Protein methylation: chemistry and beyond Session 2: Quantitative approaches to protein methylation 5:00-6:30pm Chair: Xiaobing Shi, Van Andel Research Institute 5:00-5:30pm Minkui Luo, Memorial Sloan Kettering Cancer Center 5:30-6:00pm Axel Imhof, Ludwig Maximilian University of Munich 6:00-6:15pm Scott Rothbart, Van Andel Research Institute 6:15-6:30pm George Zheng, Emory University 6:30-6:45pm Joshua Hamey, The University of New South Wales 7:00-8:00pm DINNER 5:00-8:00pm Conference Registration 8:00-10:00pm POSTER SESSION 1 Tuesday, June 19 7:30-9:00am BREAKFAST Session 3: Protein methylation in development and disease 9:00-12:15pm Chair: Maria Elena Torres-Padilla, Helmholtz Zentrum Muenchen 9:00-9:30am Jürg Müller, Max Planck Institute of Biochemistry 9:30-10:00am Jonathan Whetstine, Harvard Medical School 10:00-10:15am Clare Davies, University of Birmingham 10:15-10:30am Jian Jin, Icahn School of Medicine at Mount Sinai 10:30-10:45am Coffee break 10:45-11:15am Rob Klose, University of Oxford 11:15-11:45am Or Gozani, Stanford University 11:45-12:00pm Pål Falnes, University of Oslo 12:00-12:15pm Jian Xu, University of Southern California 12:15-1:15pm LUNCH 1:15-5:00pm FREE AFTERNOON Session 4: Arginine methylation: players and mechanisms 5:00-7:00pm Chair: Ernesto Guccione, Institute of Molecular and Cell Biology 5:00-5:30pm Mark Bedford, MD Anderson Cancer Center 5:30-6:00pm Stéphane Richard, McGill University 6:00-6:30pm Ernesto Guccione, Institute of Molecular and Cell Biology - A Star 6:30-6:45pm Humaira Gowher, Purdue University 6:45-7:00pm Kanishk Jain, University of California, Los Angeles 7:00-8:00pm DINNER 8:00-10:00pm POSTER SESSION 2 Wednesday, June 20 7:30-9:00am BREAKFAST Session 5: Modifications of nucleic acids 9:00-12:15pm Chair: Taiping Chen, MD Anderson Cancer Center 9:00-9:30am Peter Jones, Van Andel Research Institute 9:30-10:00am Anjana Rao, La Jolla Institute for Allergy and Immunology 10:00-10:30am Steve Jacobsen, University of California, Los Angeles 10:30-10:45am Coffee break 10:45-11:15am Andrew Xiao, Yale University 11:15-11:45am Mark Dawson, Peter MacCallum Cancer Centre 11:45-12:00pm Greg Wang, University of North Carolina at Chapel Hill 12:00-12:15pm Roopa Thapar, MD Anderson Cancer Center 12:15-1:15pm LUNCH 1:15-7:00pm FREE AFTERNOON 7:00-8:00pm DINNER TECHNOLOGY WORKSHOP SESSION 8:00-9:30pm Chair: Mark Bedford, MD Anderson Cancer Center 8:00-8:15pm Spencer Haws, UW-Madison 8:15-8:30pm Olena Barbash, GSK 8:30-8:40pm Sriharsa Pradhan, NEB 8:45-9:00pm Shikhar Sharma, Pfizer 9:00-9:15pm Said Goueli, Promega 9:15-9:30pm Johannes Bacher, University of Freiburg Thursday, June 21 7:30-9:00am BREAKFAST Session 6: Modulating methylation in disease and aging 9:00-12:15pm Chair: Yali Dou, University of Michigan 9:00-9:30am Yang Shi, Harvard Medical School 9:30-10:00am Taiping Chen, MD Anderson Cancer Center 10:00-10:15am Ryan Kruger, GSK 10:15-10:30am Erin Green, University of Maryland 10:30-10:45am Coffee break 10:45-11:15am Yali Dou, University of Michigan 11:15-11:45am Panagis Filippakopoulos, Ludwig Institute for Cancer 11:45-12:00pm Qin Yan, Yale University 12:00-12:15pm Dan Levy, Ben-Gurion University 12:15-1:15pm LUNCH 1:15-4:30pm FREE AFTERNOON Session 7: Structural insights to protein methylation 4:30-6:30pm Chair: Robert Schneider, Helmholtz Centre Munich 4:30-5:00pm Xiaodong Cheng, MD Anderson Cancer Center 5:00-5:30pm Cheryl Arrowsmith, Structural Genomics Consortium 5:30-6:00pm Tatiana Kutateladze, University of Colorado 6:00-6:30pm Rui-Ming Xu, Chinese Academy of Sciences 7:00-8:00pm DINNER Session 8: Methylation and Therapeutics 8:00-9:30pm Chair: Qin Yan, Yale University 8:00-8:30pm Karsten Rippe, Universität Heidelberg 8:30-8:45pm Anita Raposo, Western Sydney University 8:45-9:00pm Evelyne Lima Fernandes, University of Toronto 9:00-9:15pm Shatha AbuHammad, Peter MacCallum Cancer Centre 9:15-9:30pm Business meeting Friday, June 22 7:30-9:00am BREAKFAST Session 9: Methylation dynamics and transcription control 9:00-12:15pm Chair: Fei Lan, Fudan University 9:00-9:30am Kai Ge, NIH 9:30-9:45am Christine Schaner Tooley, SUNY Buffalo 9:45-10:00am Nicolas Reynoird, Grenoble-Alpes University 10:00-10:15am Donghang Cheng, MD Anderson Cancer Center 10:15-10:30am Tiziana Bonaldi, European Institute of Oncology 10:30-10:45am Coffee break 10:45-11:15am Anja Groth, University of Copenhagen 11:15-11:30am Coralie Poulard, University of Southern California 11:30-11:45am Fei Lan, Fudan University 11:45-12:00pm Closing Remarks 12:00-1pm LUNCH and DEPART END OF CONFERENCE For additional information contact: FASEB Science Research Conferences 9650 Rockville Pike, Bethesda, MD 20814 www.faseb.org/src .
Load more

Recommended publications
  • The Molecular Hallmarks of Epigenetic Control
    PERSPECTIVES EPIGENETICS mainly highlight important mechanistic TIMELINE and conceptual advances. Seminal primary papers are cited, but for in-depth discussions The molecular hallmarks of epigenetic and additional references the reader is at times referred to the textbook Epigenetics3 control or other timely reviews. Foundation of epigenetics C. David Allis and Thomas Jenuwein Pioneering work carried out between Abstract | Over the past 20 years, breakthrough discoveries of chromatin-modifying 1869 and 1928 by Miescher, Flemming, Kossel and Heitz defined nucleic acids, enzymes and associated mechanisms that alter chromatin in response to chromatin and histone proteins, which physiological or pathological signals have transformed our knowledge of led to the cytological distinction between epigenetics from a collection of curious biological phenomena to a functionally euchromatin and heterochromatin4 (FIG. 1a). dissected research field. Here, we provide a personal perspective on the This was followed by ground-breaking 5 development of epigenetics, from its historical origins to what we define as studies by Muller (in Drosophila melanogaster) and McClintock6 (in maize) ‘the modern era of epigenetic research’. We primarily highlight key molecular on position-effect variegation (PEV) and mechanisms of and conceptual advances in epigenetic control that have changed transposable elements, providing early our understanding of normal and perturbed development. hints of non-Mendelian inheritance. Descriptions of the phenomena of X-chromosome inactivation7
    [Show full text]
  • Protecting the Code Human Tumours
    But can these bacteria be used to treat human cancers? Future exper- iments are required to answer safety questions, as the rapid destruction of large tumours was toxic and caused the death of some animals. It will also be important to deter- mine the mechanism by which C. novyi selectively destroys viable tumour cells that are adjacent to hypoxic areas. The authors also point out that not all tumours will GENOMIC INSTABILITY be susceptible to COBALT, and they will have to determine which chemotherapeutic drugs act syner- gistically with bacteria against Protecting the code human tumours. Kristine Novak References and links A code of post-translational modifications — with none of the wild-type mice. Karotypic ORIGINAL RESEARCH PAPER Dang, L. H., including methylation, acetylation and analysis of the lymphomas revealed that some Bettegowda, C., Husa, D. L., Kinzler, K. W. & phosphorylation — in the amino termini of had ‘butterfly’ chromosomes, which did not Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. histones determines the level of chromatin segregate as they remained attached at their Natl Acad. Sci. (2001) Nov 27; [epub ahead of compaction. Histone acetylation is now centromeric regions. Could this be due to an print] recognized as an important therapeutic target in effect on the pericentric heterochromatin region FURTHER READING Sznol, M. et al. Use of preferentially replicating bacteria for the treatment cancer, but what about other histone in these cells? of cancer. J. Clin. Invest. 105, 1027–1030 (2000) modifications? Thomas Jenuwein’s group now The authors used an antibody that acts as a WEB SITE Bert Vogelstein’s lab: http://www.med.jhu.edu/ provides the first indication that histone marker of heterochromatin — by specifically pharmacology/pages/faculty/vogelstein.html methylation might also influence tumour recognizing H3 methylated at Lys9 — to show formation, by regulating genome stability.
    [Show full text]
  • Histone Modifications and Cancer
    Downloaded from http://cshperspectives.cshlp.org/ on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Histone Modifications and Cancer James E. Audia1 and Robert M. Campbell2 1Constellation Pharmaceuticals, Cambridge, Massachusetts 02142; 2Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 Correspondence: [email protected] SUMMARY Histone posttranslational modifications represent a versatile set of epigenetic marks involved not only in dynamic cellular processes, such as transcription and DNA repair, but also in the stable maintenance of repressive chromatin. In this article, we review many of the key and newly identified histone modifi- cations known to be deregulated in cancer and how this impacts function. The latter part of the article addresses the challenges and current status of the epigenetic drug development process as it applies to cancer therapeutics. Outline 1 Introduction 3 Drug-discovery challenges for histone- modifying targets 2 Histone modifications References Editors: C. David Allis, Marie-Laure Caparros, Thomas Jenuwein, Danny Reinberg, and Monika Lachner Additional Perspectives on Epigenetics available at www.cshperspectives.org Copyright # 2016 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a019521 Cite this article as Cold Spring Harb Perspect Biol 2016;8:a019521 1 Downloaded from http://cshperspectives.cshlp.org/ on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press J.E. Audia and R.M. Campbell OVERVIEW Cancer is a diverse collection of diseases characterized by the Collectively, the combination of histone marks found in dysregulation of important pathways that control normal cel- a localized region of chromatin function through multiple lular homeostasis. This escape from normal control mecha- mechanisms as part of a “chromatin-based signaling” system nisms leads to the six hallmarks of cancer, which include (Jenuwein and Allis 2001; Schreiber and Bradley 2002).
    [Show full text]
  • DNA Methylation of Intragenic Cpg Islands Depends on Their Transcriptional Activity During Differentiation and Disease
    DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease Danuta M. Jeziorskaa, Robert J. S. Murrayb,c,1, Marco De Gobbia,2, Ricarda Gaentzscha,3, David Garricka,4, Helena Ayyuba, Taiping Chend,EnLie, Jelena Teleniusa, Magnus Lyncha,5, Bryony Grahama, Andrew J. H. Smitha,f, Jonathan N. Lundc, Jim R. Hughesa, Douglas R. Higgsa,6, and Cristina Tufarellic,6 aMedical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, United Kingdom; bDepartment of Genetics, University of Leicester, Leicester LE1 7RH, United Kingdom; cDivision of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, United Kingdom; dDepartment of Epigenetics and Molecular Carcinogenesis, Division of Basic Science Research, The University of Texas M. D. Anderson Cancer Center, Smithville, TX 78957; eChina Novartis Institutes for BioMedical Research, Shanghai 201203, China; and fMedical Research Council Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh EH16 4UU, United Kingdom Edited by Adrian P. Bird, University of Edinburgh, Edinburgh, United Kingdom, and approved July 28, 2017 (received for review February 23, 2017) The human genome contains ∼30,000 CpG islands (CGIs). While CGIs (RHBDF1), which becomes methylated during normal devel- associated with promoters nearly always remain unmethylated, many opment in vivo (11) (Fig. 1). of the ∼9,000 CGIs lying within gene bodies become methylated during In both cases, we show that methylation of these specific CGIs development and differentiation. Both promoter and intragenic CGIs is associated with transcription traversing the CGI, a reduction of may also become abnormally methylated as a result of genome rear- H3K4me3, a gain of H3K36me3, and DNA methyltransferase 3B rangements and in malignancy.
    [Show full text]
  • Drosophila CAF-1 Regulates HP1-Mediated Epigenetic Silencing and Pericentric Heterochromatin Stability
    Research Article 2853 Drosophila CAF-1 regulates HP1-mediated epigenetic silencing and pericentric heterochromatin stability Hai Huang1,2, Zhongsheng Yu1,2, Shuaiqi Zhang1, Xuehong Liang1, Jianming Chen3, Changqing Li1, Jun Ma1,4 and Renjie Jiao1,* 1State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences, Datun Road 15, Beijing 100101, China 2Graduate School of the Chinese Academy of Sciences, Beijing 100080, China 3Third Institute of Oceanography, State Oceanic Administration, University Road 178, Xiamen 361005, China 4Divisions of Biomedical Informatics and Developmental Biology, Cincinnati Children’s Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229, USA *Author for correspondence ([email protected]) Accepted 20 May 2010 Journal of Cell Science 123, 2853-2861 © 2010. Published by The Company of Biologists Ltd doi:10.1242/jcs.063610 Summary Chromatin assembly factor 1 (CAF-1) was initially characterized as a histone deliverer in the process of DNA-replication-coupled chromatin assembly in eukaryotic cells. Here, we report that CAF-1 p180, the largest subunit of Drosophila CAF-1, participates in the process of heterochromatin formation and functions to maintain pericentric heterochromatin stability. We provide evidence that Drosophila CAF-1 p180 plays a role in both classes of position effect variegation (PEV) and in the expression of heterochromatic genes. A decrease in the expression of Drosophila CAF-1 p180 leads to a decrease in both H3K9 methylation at pericentric heterochromatin regions and the recruitment of heterochromatin protein 1 (HP1) to the chromocenter of the polytene chromosomes. The artificial targeting of HP1 to a euchromatin location leads to the enrichment of Drosophila CAF-1 p180 at this ectopic heterochromatin, suggesting the mutual recruitment of HP1 and CAF-1 p180.
    [Show full text]
  • Current Evidence for a Role of Epigenetic Mechanisms in Response to Ionizing Radiation in an Ecotoxicological Context N
    Current evidence for a role of epigenetic mechanisms in response to ionizing radiation in an ecotoxicological context N. Horemans, D.J. Spurgeon, C. Lecomte-Pradines, E. Saenen, C. Bradshaw, D. Oughton, I. Rasnaca, J.H. Kamstra, C. Adam-Guillermin To cite this version: N. Horemans, D.J. Spurgeon, C. Lecomte-Pradines, E. Saenen, C. Bradshaw, et al.. Current ev- idence for a role of epigenetic mechanisms in response to ionizing radiation in an ecotoxicological context. Environmental Pollution, Elsevier, 2019, 251, pp.469-483. 10.1016/j.envpol.2019.04.125. hal-02524800 HAL Id: hal-02524800 https://hal.archives-ouvertes.fr/hal-02524800 Submitted on 7 Jul 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License Manuscript Details Manuscript number ENVPOL_2019_714_R1 Title Current evidencefor a role of epigenetic mechanisms in response to ionizing radiation in an ecotoxicological context Article type Review Article Abstract The issue of potential long-term or hereditary effects for both humans and wildlife exposed to low doses (or dose rates) of ionising radiation is a major concern. Chronic exposure to ionising radiation, defined as an exposure over a large fraction of the organism's lifespan or even over several generations, can possibly have consequences in the progeny.
    [Show full text]
  • G2 Histone Methylation Is Required for the Proper Segregation of Chromosomes
    Research Article 2957 G2 histone methylation is required for the proper segregation of chromosomes Ryan Heit1, Jerome B. Rattner2, Gordon K. T. Chan1 and Michael J. Hendzel1,* 1Department of Oncology, Faculty of Medicine, University of Alberta, Edmonton, Canada T6G 1Z2 2Departments of Cell Biology and Anatomy, Biochemistry and Molecular Biology, and Oncology, Faculty of Medicine, University of Calgary, Calgary, Canada T2N 4N1 *Author for correspondence ([email protected]) Accepted 18 May 2009 Journal of Cell Science 122, 2957-2968 Published by The Company of Biologists 2009 doi:10.1242/jcs.045351 Summary Trimethylation of lysine 9 on histone H3 (H3K9me3) is known pericentric heterochromatin might be responsible for a noted both to be necessary for proper chromosome segregation and loss of tension at the centromere in AdOx-treated cells and to increase in late G2. We investigated the role of late G2 activation of the spindle assembly checkpoint. We postulate that methylation, specifically in mitotic progression, by inhibiting late G2 methylation is necessary for proper pericentric methylation for 2 hours prior to mitosis using the general heterochromatin formation. The results suggest that a reduction methylation inhibitor adenosine dialdehyde (AdOx). AdOx in heterochromatin integrity might interfere both with inhibits all methylation events within the cell but, by shortening microtubule attachment to chromosomes and with the proper the treatment length to 2 hours and studying mitotic cells, the sensing of tension from correct microtubule-kinetochore only methylation events that are affected are those that occur connections, either of which will result in activation of the in late G2. We discovered that methylation events in this time mitotic checkpoint.
    [Show full text]
  • Evidence of Polycomb-Independent Catalysis of Histone H3 Lysine 27
    Evidence of Polycomb-independent Catalysis of Histone H3 Lysine 27 Trimethylation by Lorenza Donnelly An honors thesis submitted in partial fulfillment of the requirements for graduation with Honors in the degree of Bachelors of Science in Cellular and Molecular Biology at the University of Michigan May 2014 Sponsor: Sundeep Kalantry, PhD. Assistant Professor Department of Human Genetics University of Michigan Medical School TABLE OF CONTENTS ABSTRACT……………………………………………………………………………………...2 INTRODUCTION………………………………………………………………………………..3 RESULTS……………………...……………………………………………………………….10 H3K27me3 catalysis in Ezh2-/- XEN cells.........................................................10 H3K27me3 catalysis in Ezh2-/-;Ezh1-/- XEN cells..............................................14 H3K27me3 catalysis in Eed-/- XEN cells...........................................................20 DISCUSSION...……………………………………………………………………………......24 METHODS......................................................................................................................28 ACKNOWLEDGEMENTS..............................................................................................35 REFERENCES...............................................................................................................36 1 ABSTRACT Transcriptional regulation can occur through the modification and remodeling of chromatin, which consists of DNA, histones, and non-histone proteins. One such mechanism that controls gene expression is the chemical modification of histones. The Polycomb
    [Show full text]
  • July Book.Indd
    BOOKS Epigenetics for big and small species, suggesting a fundamental role in a number of cellular events. Epigenetics The rich plethora of these modifications, the identification of proteins that bind to some of these modifications and the diversity of the func- Edited by C. David Allis, Thomas tional output associated with various modifications have paved the way Jenuwein & Danny Reinberg for a more molecular definition of epigenetics. Epigenetics is defined by Associate editor: Maire-Laure Caparros Allis, Jenuwein and Reinberg in the book as “the sum of the alterations to the chromatin template that collectively establish and propagate dif- Cold Spring Harbor Press 2007 ferent patterns of gene expression (transcription) and silencing from the same genome”. Although it is clear that DNA methylation is epigenetic £85/$150 in the classical meaning of the term, it remains to be seen how many of the histone modifications will follow this rule. Reviewed by Asifa Akhtar From a historical perspective, epigenetics has been viewed as a col- lection of a number of interesting phenomena, such as position effect The availability of the human genome sequence has opened new avenues variegation in Drosophila, X inactivation and imprinting in mammals, to broaden our understanding of human biology. Certainly, this infor- or paramutation in maize. These processes, although unique in their mation is key to facilitating examination of the molecular similarities own right, have intriguing similarities at the molecular level, especially and differences between individuals in the normal and diseased state. when it comes to certain histone modifications. These disparate observa- However, it is also becoming increasingly evident that knowledge of the tions have brought together scientists from various fields, such as RNA DNA sequence of chromosomes does not completely reflect the genetic interference, heterochromatin formation, prion proteins and research- complexity of an organism.
    [Show full text]
  • Dicer-Deficient Mouse Embryonic Stem Cells Are Defective in Differentiation and Centromeric Silencing
    Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing Chryssa Kanellopoulou,1,4 Stefan A. Muljo,2,4 Andrew L. Kung,1 Shridar Ganesan,1 Ronny Drapkin,1 Thomas Jenuwein,3 David M. Livingston,1,5 and Klaus Rajewsky2,6 1The Dana-Farber Cancer Institute, Department of Cancer Biology and 2The CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA; 3Research Institute of Molecular Pathology, The Vienna Biocenter, A-1030 Vienna, Austria Dicer is the enzyme that cleaves double-stranded RNA (dsRNA) into 21–25-nt-long species responsible for sequence-specific RNA-induced gene silencing at the transcriptional, post-transcriptional, or translational level. We disrupted the dicer-1 (dcr-1) gene in mouse embryonic stem (ES) cells by conditional gene targeting and generated Dicer-null ES cells. These cells were viable, despite being completely defective in RNA interference (RNAi) and the generation of microRNAs (miRNAs). However, the mutant ES cells displayed severe defects in differentiation both in vitro and in vivo. Epigenetic silencing of centromeric repeat sequences and the expression of homologous small dsRNAs were markedly reduced. Re-expression of Dicer in the knockout cells rescued these phenotypes. Our data suggest that Dicer participates in multiple, fundamental biological processes in a mammalian organism, ranging from stem cell differentiation to the maintenance of centromeric heterochromatin structure and centromeric silencing. [Keywords: RNA interference; microRNA; heterochromatin silencing; DNA methylation] Supplemental material is available at http://www.genesdev.org. Received August 11, 2004; revised version accepted December 14, 2004. Central to the RNA interference (RNAi) machinery is mammals, where a single dicer gene likely exists, the RNase III-containing enzyme, Dicer (Bernstein et al.
    [Show full text]
  • DNA Methylation and Complete Transcriptional Silencing of Cancer Genes Persist After Depletion of EZH2 Kelly M
    Priority Report DNA Methylation and Complete Transcriptional Silencing of Cancer Genes Persist after Depletion of EZH2 Kelly M. McGarvey,1,2 Eriko Greene,1,2 Jill A. Fahrner,1,2 Thomas Jenuwein,3 and Stephen B. Baylin1 1The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University; 2The Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3Research Institute of Molecular Pathology, The Vienna Biocenter, Vienna, Austria Abstract decrease in global DNA methylation and gene re-expression after Recent work suggests a link between the polycomb group introduction of a dominant-negative H3K27R mutant in ovarian protein EZH2 and mediation of gene silencing in association cancer cells, although a reduction in promoter DNA methylation is with maintenance of DNA methylation. However,we show that not observed (13). Importantly, the effects of a lysine-to-arginine whereas basally expressed target cancer genes with minimal substitution may be less specific than a discrete loss of H3K27me3, DNA methylation have increased transcription during EZH2 as evidenced by a greater reduction in global DNA methylation in knockdown,densely DNA hypermethylated and silenced genes the K27R mutant compared with EZH2 knockdown (13). Another retain their methylation and remain transcriptionally silent. recent study used small interferingRNA (siRNA) to reduce EZH2 These results suggest that EZH2 can modulate transcription of levels in an osteosarcoma cell line and proposed that EZH2 directly controls both initiation and maintenance of DNA methylation (14). basally expressed genes but not silent genes that are densely However, we now present findings suggesting that although EZH2 DNA methylated.
    [Show full text]
  • BIOLOGY & MEDICINE Epigenetics
    BIOLOGY & MEDICINE_Epigenetics Histones are important proteins for epigenetics. Consequently, delegates at the Epigenetics Conference are greeted with the amino acid code of the histone protein H3. 56 MaxPlanckResearch 2 | 11 Operating the Genome Switches Research into epigenetics is a rapidly growing field. A recent conference at the Max Planck Institute of Immunobiology in Freiburg shed light on the reasons. The new science investigates permanent biochemical switches that control genetic activity. These switches give a cell its identity and memory. They are what enable organisms to develop and adapt to their environment. TEXT PETER SPORK he different types presented genome that, while having no effect on by Shelley Berger display an the genes themselves, still determine amazing variety. “One is a typ- which of them can use a somatic cell ical command receiver,” ex- and which can’t. These structures de- plains the cell biologist, “while fine the way a cell is built and how it T the next one tells the first what to do.” functions by means of a gene activation And the third is not only the boss – on program. Berger shows what this does top of that, it lives a lot longer than the to the ants. She states that, in the ge- others and is the only one that is fer- nome of brain cells, there are systemat- tile. Although it is not too surprising ic, non-genetic differences that ensure that such differences occur, what is as- that the subordinate female worker tonishing is that the three types have ants are more sensitive than their dom- identical genomes.
    [Show full text]